News
Should We Bring CAR-T Therapy Home Sooner?
Chimeric Antigen Receptor (CAR) T-cell therapy is already making a significant impact in treating various blood cancers, including multiple myeloma. Currently, two CAR T-cell therapies
As we explore the complexities of Multiple Myeloma, we uncover exciting opportunities to revolutionize patient care and address the many unmet needs that exist today. From enhancing early diagnosis to transforming the treatment landscape for relapsing cases, there’s a tremendous scope for breakthroughs that could significantly improve outcomes and bring us closer to our ultimate vision—a world free from Multiple Myeloma.
Ongoing projects are paving the way, but the journey is far from over. D2in2M2 is actively seeking innovative ideas and initiatives that can help push the boundaries of what’s possible in the fight against this challenging disease. Stay tuned as we launch new projects and take bold steps forward in our mission to transform the future of Multiple Myeloma care.
Chimeric Antigen Receptor (CAR) T-cell therapy is already making a significant impact in treating various blood cancers, including multiple myeloma. Currently, two CAR T-cell therapies
Recently, the term “care partner” has gained popularity to describe those assisting myeloma patients. However, it’s essential to distinguish between a primary care partner and
On Friday, March 15, 2024; the U.S. Food and Drug Administration (FDA) held an Oncologic Drugs Advisory Committee (ODAC) meeting to assess the risk-benefit profile
For myeloma patients, the word “cure” holds immense significance—it’s like the elusive pot of gold at the end of the rainbow, often feeling like a
Measles has been making headlines recently, with 121 cases reported in the U.S. so far this year. To understand the level of concern for myeloma
A segment on last Sunday’s edition of 60 Minutes highlighted the remarkable effects of injecting poliovirus into brain tumors. Three years after receiving the poliovirus
As we head into fall, a new COVID-19 subvariant, EG.5 (nicknamed Eris), is rapidly gaining dominance in the U.S. This variant, classified as a “variant
Chimeric Antigen Receptor (CAR) T-cell therapy is already making a significant impact in treating various blood cancers, including multiple myeloma. Currently, two CAR T-cell therapies
Several significant events took place this week: the 22nd anniversary of the 9/11 attacks in New York City, the FDA’s approval and CDC’s endorsement of
